ReviewFrontiers in medicine2026
Fu's subcutaneous needling: a traditional acupuncture radiating new therapeutic potentials.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fu's subcutaneous needling (FSN) is a brainchild of conventional acupuncture and modern medicine. It is initially used to mask pain in musculoskeletal conditions by directly stimulating the subcutaneous tissue using a special trocar needle. Currently, the modern clinical indications for FSN are gradually expanding. Methods: Through literature review of FSN in treating pain and non-pain conditions published from 1 Results: FSN is initially created to relieve pain conditions through the core mechanisms of tightened muscle and reperfusion approach. It is now radiated into the treatment of non-pain conditions like lower gastrointestinal disorders by indirectly manipulating a neuro-endocrine-immune network, possessing high efficacy and safety profile. Conclusion: This review provides new insights into FSN in alleviating pain and non-pain conditions, especially in treating lower gastrointestinal and/or anorectal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.